Anti-HIV Activity and Safety of 3 Different Doses of Mifepristone in HIV Infected People

Inclusion Criteria: * HIV-1 infected * CD4 count of 350 cells/mm3 or more within 90 days prior to study entry * HIV-1 viral load of 2000 copies/ml or more within 90 days prior to study entry * Willing to use acceptable forms of contraception during the study and for 30 days after stopping study medication * If currently taking precautionary concomitant medications, must be on stable doses for more than 8 weeks prior to study entry and have no plans to change medications or doses for the duration of the study * Body weight at least 40 kg (88 lbs) within 90 days prior to study entry Exclusion Criteria: * Antiretroviral treatment (ART) within 16 weeks prior to study entry, or intend to start ART within 60 days after entry * Adrenal disorders * History of autoimmune endocrine disease in self or family * History of active hepatitis B or C * Current treatment for hepatitis B or C * Moderate to severe liver disease * Blood disorders or current anticoagulant therapy * Prior pituitary tumor, surgery, radiation treatment, or pituitary failure * Moderate to large goiters or thyroid nodules * Diabetes mellitus * Unusual uterine bleeding within 12 months prior to study entry * Current hormonal contraception or intrauterine (IUD) use, including progesterone-containing vaginal rings * Pregnancy within 90 days prior to study entry * Breast-feeding * Drugs that act as inhibitors or inducers of metabolism by cytochrome P450 3A4 * Systemic corticosteroids or hormonal agents within 90 days prior to study entry * Any immunomodulator, HIV vaccine, or investigational therapy within 90 days prior to study entry * Any vaccination within 30 days prior to study entry * Systemic cytotoxic chemotherapy within 90 days prior to study entry * History of allergy to mifepristone or the study formulations * Current drug or alcohol abuse that, in the opinion of the investigator, may interfere with the study * Any other conditions that may interfere with participant evaluation during the study * Serious illness requiring systemic treatment or hospitalization. Patients who complete therapy or are clinically stable on therapy for at least 14 days prior to study entry are not excluded.